International Journal of Molecular Sciences (Dec 2023)

<i>In Vivo</i> and <i>In Silico</i> Studies of the Hepatoprotective Activity of <i>Tert</i>-Butylhydroquinone

  • Liseth Rubi Aldaba-Muruato,
  • Sandra Sánchez-Barbosa,
  • Víctor Hugo Rodríguez-Purata,
  • Georgina Cabrera-Cruz,
  • Estefany Rosales-Domínguez,
  • Daniela Martínez-Valentín,
  • Yoshio Aldo Alarcón-López,
  • Pablo Aguirre-Vidal,
  • Manuel Alejandro Hernández-Serda,
  • Luis Alfonso Cárdenas-Granados,
  • Víctor Hugo Vázquez-Valadez,
  • Enrique Angeles,
  • José Roberto Macías-Pérez

DOI
https://doi.org/10.3390/ijms25010475
Journal volume & issue
Vol. 25, no. 1
p. 475

Abstract

Read online

Tert-butylhydroquinone (TBHQ) is a synthetic food antioxidant with biological activities, but little is known about its pharmacological benefits in liver disease. Therefore, this work aimed to evaluate TBHQ during acute liver damage induced by CCl4 (24 h) or BDL (48 h) in Wistar rats. It was found that pretreatment with TBHQ prevents 50% of mortality induced by a lethal dose of CCl4 (4 g/kg, i.p.), and 80% of BDL+TBHQ rats survived, while only 50% of the BDL group survived. Serum markers of liver damage and macroscopic and microscopic (H&E staining) observations suggest that TBHQ protects from both hepatocellular necrosis caused by the sublethal dose of CCl4 (1.6 g/kg, i.p.), as well as necrosis/ductal proliferation caused by BDL. Additionally, online databases identified 49 potential protein targets for TBHQ. Finally, a biological target candidate (Keap1) was evaluated in a proof-of-concept in silico molecular docking assay, resulting in an interaction energy of −5.5491 kcal/mol, which was higher than RA839 and lower than monoethyl fumarate (compounds known to bind to Keap1). These findings suggest that TBHQ increases the survival of animals subjected to CCl4 intoxication or BDL, presumably by reducing hepatocellular damage, probably due to the interaction of TBHQ with Keap1.

Keywords